Neighborhood Deprivation Linked to Worse Melanoma Survival in Thin Tumor Study

When most people think about the odds of surviving melanoma, the deadliest form of skin cancer, they tend to think about biology: how deeply the tumor has invaded the skin, whether it has spread to lymph nodes, and which mutations are driving its growth. A new study from researchers at Johns Hopkins University School of Medicine adds a different and often overlooked variable to that equation, one that has nothing to do with the tumor itself and everything to do with the neighborhood a patient calls home. The research, published as a research letter in the Archives of Dermatological Research, examines whether area-level socioeconomic deprivation is associated with melanoma-specific mortality among patients diagnosed with thin melanomas, the earliest and typically most curable stage of the disease.

Thin melanoma, generally defined as an invasive melanoma measuring one millimeter or less in Breslow thickness, carries an excellent prognosis when caught early, and most patients with these lesions are cured with wide local excision alone. That is precisely why the new findings are striking. If even patients with thin, apparently low-risk melanomas face unequal survival odds depending on where they live, it suggests that the mechanisms driving melanoma deaths operate well before and well after the moment of diagnosis, shaped by access to care, follow-up surveillance, and broader social conditions rather than tumor biology alone.

The study, led by Maria Kaltchenko of the Department of Dermatology at Johns Hopkins and supervised by Joel Sunshine and Kristin Bibee, took the form of a retrospective cohort study, a design in which investigators look backward at existing medical records to compare outcomes across groups defined by an exposure of interest. In this case, the cohort consisted of patients referred to a high-risk specialty clinic, a population that is already under heightened surveillance for skin cancer. The exposure was area deprivation, measured not by individual income or education but by a composite index attached to the patient’s residential neighborhood.

Area deprivation indices have become one of the most widely used tools in health disparities research. Rather than relying on self-reported income, which is frequently missing from medical records and difficult to verify, these indices aggregate census-derived variables such as household income, unemployment, education, and housing quality for the small geographic area in which a person lives. The result is a percentile score that situates each patient’s neighborhood on a spectrum from least to most disadvantaged. The approach was popularized in part by the Neighborhood Atlas project described in the New England Journal of Medicine byKind and Buckingham, which made neighborhood disadvantage metrics freely accessible so that researchers and clinicians could link them to health records. The appeal is straightforward: a single, reproducible number captures a web of social conditions, from transportation access and food insecurity to housing instability and the local availability of medical services.

Why would neighborhood deprivation matter for a cancer that is, in principle, highly survivable? The answer likely lies in the full arc of the disease, from prevention to long-term follow-up. Melanoma detection depends on skin awareness, access to dermatologic evaluation, and the ability to act on a suspicious lesion quickly. Patients in deprived neighborhoods may face barriers at every one of these steps: fewer dermatologists nearby, less flexibility to take time off work for appointments, lower rates of skin self-examination, and delayed presentation once a lesion is noticed. After diagnosis, surveillance matters enormously. Patients with a history of melanoma require regular full-body skin examinations, and recurrences or second primary melanomas caught early are far more treatable than those discovered late. Missing follow-up appointments, whether because of cost, transportation, or competing life demands, can translate into later-stage detection of new disease.

The Johns Hopkins team chose to study a high-risk referral cohort for a specific methodological reason. Patients referred to specialty melanoma and high-risk skin cancer clinics typically receive uniform, protocolized care: standardized follow-up intervals, systematic total-body skin examinations, and consistent patient education. By studying outcomes within such a cohort, investigators can partly neutralize the confounding effect of variable treatment quality. If deprivation is still associated with melanoma-specific death even among patients receiving comparable specialist care, that points toward factors that operate outside the clinic, in the periods before diagnosis and between visits, or in differences in comorbid health, immune function, and health behaviors that cluster with socioeconomic disadvantage.

Melanoma-specific mortality is a deliberately precise endpoint. Rather than counting deaths from any cause, which would obscure the picture in an older cohort where cardiovascular disease and other cancers are common, researchers track deaths attributable to melanoma itself. This distinction matters because prior work has shown that patients with thin melanomas are actually more likely to die of something other than their melanoma. A large study by Lo and colleagues published in JAMA Dermatology in 2024 examined the risk of death due to melanoma versus other causes in patients with thin cutaneous melanomas and highlighted this competing-risk landscape. Any analysis of melanoma-specific death in a thin melanoma population must therefore grapple with the fact that melanoma deaths, while devastating, are statistically the minority of deaths in this group, which demands careful statistical handling and large, well-characterized cohorts.

The broader literature on socioeconomic status and cancer outcomes provides consistent context for the new study. Research published in JAMA Network Open by Cheng and colleagues in 2021 found that both neighborhood-level and individual-level socioeconomic disadvantage were associated with worse survival across multiple common nonmetastatic cancers, suggesting that the effect is not unique to melanoma. In dermatology specifically, Cortez, Vasquez, and Wei reviewed the impact of demographics, socioeconomics, and health care access on melanoma outcomes in the Journal of the American Academy of Dermatology, and Rosenthal and colleagues documented disparities in melanoma-specific mortality by race, ethnicity, socioeconomic status, and health care system factors. What the Johns Hopkins study adds is a focused look at the thin melanoma population, a group in whom tumor biology should confer a strong survival advantage, and an assessment of whether neighborhood deprivation erodes that advantage even within a high-risk referral setting.

The implications of the research reach beyond academic curiosity. If area deprivation independently predicts melanoma death, then the conventional risk stratification used in clinics, which relies almost entirely on tumor thickness, ulceration, mitotic rate, and patient age, is incomplete. Incorporating neighborhood disadvantage metrics into risk assessment could identify patients who warrant closer surveillance, more intensive patient education, or structured navigation services to ensure they actually attend follow-up visits. Health systems could use deprivation scores to allocate outreach resources, scheduling support, and telehealth options toward the patients least likely to otherwise maintain surveillance. At the policy level, the findings feed into a growing recognition that zip code can be as consequential for cancer survival as genetic code, and that interventions targeting the social determinants of health are, in a meaningful sense, cancer interventions.

The study also underscores how much remains to be learned about why thin melanomas, which should almost never be fatal, still claim lives. Biologic factors such as occult micrometastases at the time of diagnosis, aggressive histologic subtypes, and host immune factors all play a role. But the new work suggests that the social environment in which patients live is not merely background noise; it may be an independent and modifiable determinant of who survives. Kaltchenko and her colleagues, whose analysis was verified by co-authors and approved as exempt by the Johns Hopkins Institutional Review Board, have made their data available to other researchers upon reasonable request, an invitation for the field to build on the finding. As health systems grapple with persistent inequities in cancer outcomes, studies like this one sharpen the question from whether disadvantage matters to precisely where in the cancer care pathway it does its damage, and what can be done to interrupt it.

Subject of Research: The association between neighborhood socioeconomic deprivation and melanoma-specific mortality in patients with thin melanoma

Article Title: Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study

Article References: Kaltchenko, M., Lalwani, K., Tripathi, R., Will, E., Herrera, D. B., Chen, N., Bibee, K., & Sunshine, J. (2026). Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study. Archives of Dermatological Research, 318(1), Article 408. https://doi.org/10.1007/s00403-026-04911-1

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04911-1

Keywords: melanoma, thin melanoma, area deprivation, health disparities, melanoma-specific mortality, retrospective cohort study, dermatology, socioeconomic status, skin cancer, neighborhood disadvantage, survival outcomes, Johns Hopkins